Isomorphic Labs Raises $2.1B Series B to Industrialize Its AI Drug Design Engine

Isomorphic Labs, the AI drug-design company that spun out of Google DeepMind in 2021, said on Tuesday it has raised $2.1 billion in a Series B round led by Thrive Capital, the biggest financing yet for a startup applying frontier AI to pharmaceutical R&D. Existing backers Alphabet and GV returned for the round, and were joined by new investors MGX, Temasek, CapitalG and the United Kingdom's recently launched Sovereign AI Fund — a politically loaded lineup that underlines just how strategic governments now consider AI-native drug discovery.

The company, run by Nobel laureate Sir Demis Hassabis and president Max Jaderberg, will plough the money into what it calls IsoDDE, an end-to-end AI drug design engine built on the same lineage as the AlphaFold protein-structure models that won DeepMind a share of the 2024 Nobel Prize in Chemistry. IsoDDE folds structure prediction, generative chemistry and binding-affinity modeling into a single pipeline, with the explicit aim of letting a small team of computational chemists nominate clinical candidates in a fraction of the time and cost of a traditional wet-lab program.

Isomorphic said the fresh capital will be used to scale the engine globally, expand its therapeutic-area footprint and — most importantly for investors — advance its internal pipeline toward the clinic. The company has not disclosed which programs are closest to filing, but it maintains active collaborations with Novartis, Eli Lilly and Johnson & Johnson, several of which were initiated with cash-and-milestone structures that would convert into meaningful revenue once a candidate enters human trials.

The round comes at a moment when AI-first biotech is consolidating into a small number of very well-funded platforms. Recursion, Insilico Medicine and Xaira have all raised large checks against the same thesis, but Isomorphic's pedigree — direct lineage from AlphaFold and continued access to Google's TPU fleet — has so far given it a distinct narrative for investors looking for the single asset most likely to deliver an AI-discovered, AI-designed drug at FDA scale. Whether that translates into approved medicines remains the unanswered question that this $2.1 billion is meant to start answering.